Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

IQWiG invites to participate in the Autumn Symposium 2017

2017-09-18 How can evidence be transferred from distant countries or to other patient groups? Where are the frontiers? On 24 and 25 November 2017 experts will search for answers to these questions.  read more Link to "IQWiG invites to participate in the Autumn Symposium 2017"

Nivolumab in squamous cell carcinoma of the head and neck: added benefit for specific patients

2017-09-01 There is an indication of considerable added benefit in progression up to six months after platinum-based therapy. An added benefit is not proven for progression occurring later.  read more Link to "Nivolumab in squamous cell carcinoma of the head and neck: added benefit for specific patients"

Tenofovir alafenamide in chronic hepatitis B: added benefit not proven, data incomplete

2017-07-03 No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven.  read more Link to "Tenofovir alafenamide in chronic hepatitis B: added benefit not proven, data incomplete"

Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients

2017-06-01 There were notably more remissions than under the comparator therapies. In future, the analysis of symptoms should not be limited to improvements at one time point.  read more Link to "Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients"

Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit

2017-05-15 Good study design allows identification of the relevant subpopulation, in which prolonged overall survival notably outweighs disadvantages in some side effects.  read more Link to "Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
D16-01 Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization on the preliminary report 2017-11-06

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Nivolumab (Opdivo) for the treatment of advanced urothelial carcinoma

The drug nivolumab (trade name: Opdivo) has been approved in Germany since June 2017 for the treatment of advanced urothelial carcinoma. The drug is an option for adults with urothelial cancer that is progressing despite platinum-based chemotherapy.  read more (Link to "Nivolumab (Opdivo) for the treatment of advanced urothelial carcinoma" – opens in a new window)

to top

Glossary entries